81 related articles for article (PubMed ID: 6161319)
1. Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomic dysfunction.
Nutt JG; Mrox EA; Leeman SE; Williams AC; Engel WK; Chase TN
Neurology; 1980 Dec; 30(12):1280-5. PubMed ID: 6161319
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid immunoreactive substance P and somatostatin in neurological patients with peripheral and spinal cord disease.
Cramer H; Rösler N; Rissler K; Gagnieu MC; Renaud B
Neuropeptides; 1988 Oct; 12(3):119-24. PubMed ID: 2468107
[TBL] [Abstract][Full Text] [Related]
3. Elevated cerebrospinal fluid substance P-like immunoreactivity in patients with painful osteoarthritis, but not in patients with rhizopatic pain from a herniated lumbar disc.
Lindh C; Liu Z; Lyrenäs S; Ordeberg G; Nyberg F
Scand J Rheumatol; 1997; 26(6):468-72. PubMed ID: 9433409
[TBL] [Abstract][Full Text] [Related]
4. Objective evaluation of pain in various spinal diseases: neuropeptide immunoreactivity in the cerebrospinal fluid.
Imasato H; Nagata K; Hashimoto S; Komori H; Inoue A
Spinal Cord; 1997 Nov; 35(11):757-62. PubMed ID: 9392047
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical quantification of substance P in spinal dorsal horns of patients with multiple system atrophy.
Tomokane N; Kitamoto T; Tateishi J; Sato Y
J Neurol Neurosurg Psychiatry; 1991 Jun; 54(6):535-41. PubMed ID: 1715385
[TBL] [Abstract][Full Text] [Related]
6. Increased cerebrospinal fluid levels of substance P in patients with amyotrophic lateral sclerosis. Short communication.
Matsuishi T; Nagamitsu S; Shoji H; Itoh M; Takashima S; Iwaki T; Shida N; Yamashita Y; Sakai T; Kato H
J Neural Transm (Vienna); 1999; 106(9-10):943-8. PubMed ID: 10599876
[TBL] [Abstract][Full Text] [Related]
7. Tissue concentration and release of substance P-like immunoreactivity in the dental pulp.
Brodin E; Gazelius B; Olgart L; Nilsson G
Acta Physiol Scand; 1981 Feb; 111(2):141-9. PubMed ID: 6169251
[TBL] [Abstract][Full Text] [Related]
8. Increases of substance P-like immunoreactivity within striatal-nigral structures after subacute methamphetamine treatment.
Ritter JK; Schmidt CJ; Gibb JW; Hanson GR
J Pharmacol Exp Ther; 1984 May; 229(2):487-92. PubMed ID: 6201607
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid levels of immunoreactive substance P and somatostatin in patients with multiple sclerosis and inflammatory CNS disease.
Rösler N; Reuner C; Geiger J; Rissler K; Cramer H
Peptides; 1990; 11(1):181-3. PubMed ID: 1692993
[TBL] [Abstract][Full Text] [Related]
10. Ventricular fluid neuropeptides in Parkinson's disease. II. Levels of substance P-like immunoreactivity.
Cramer H; Jost S; Reuner C; Milios E; Geiger J; Mundinger F
Neuropeptides; 1991 Feb; 18(2):69-73. PubMed ID: 1708113
[TBL] [Abstract][Full Text] [Related]
11. Substance P mechanism in cluster headache: evaluation in plasma and cerebrospinal fluid.
Sicuteri F; Fanciullacci M; Geppetti P; Renzi D; Caleri D; Spillantini MG
Cephalalgia; 1985 Sep; 5(3):143-9. PubMed ID: 2412704
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients.
Cramer H; Rissler K; Rösler N; Strubel D; Schaudt D; Kuntzmann F
Eur Neurol; 1989; 29(1):1-5. PubMed ID: 2468498
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.
Cramer H; Schaudt D; Rissler K; Strubel D; Warter JM; Kuntzmann F
J Neurol; 1985; 232(6):346-51. PubMed ID: 2416886
[TBL] [Abstract][Full Text] [Related]
14. Substance P in human tears.
Yamada M; Ogata M; Kawai M; Mashima Y; Nishida T
Cornea; 2003 Oct; 22(7 Suppl):S48-54. PubMed ID: 14703707
[TBL] [Abstract][Full Text] [Related]
15. Development of substance P-like immunoreactivity in Xenopus embryos.
Gallagher BC; Moody SA
J Comp Neurol; 1987 Jun; 260(2):175-85. PubMed ID: 2440913
[TBL] [Abstract][Full Text] [Related]
16. [Fibrin fibrinogen degradation products in the cerebrospinal fluid of neurological patients].
Nowak S; Zioło H; Błaszczyk B
Neurol Neurochir Pol; 1984; 18(6):541-5. PubMed ID: 6100318
[TBL] [Abstract][Full Text] [Related]
17. Prevaccination with diluted Freund adjuvant prevents the development of chronic pain and transient release of cerebrospinal fluid substance P in adjuvant-induced arthritis in rats.
Calvino B; Couraud JY; Besson JM
Pain; 1994 Aug; 58(2):211-217. PubMed ID: 7529393
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid neurotransmitter changes during the perioperative period in patients undergoing total knee replacement: a randomized trial.
Buvanendran A; Kroin JS; Della Valle CJ; Moric M; Tuman KJ
Anesth Analg; 2012 Feb; 114(2):434-41. PubMed ID: 22156332
[TBL] [Abstract][Full Text] [Related]
19. Decreased cerebrospinal fluid levels of substance P in patients with Rett syndrome.
Matsuishi T; Nagamitsu S; Yamashita Y; Murakami Y; Kimura A; Sakai T; Shoji H; Kato H; Percy AK
Ann Neurol; 1997 Dec; 42(6):978-81. PubMed ID: 9403492
[TBL] [Abstract][Full Text] [Related]
20. Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease.
Cramer H; Wolf A; Rissler K; Weigel K; Ostertag C
J Neurol; 1985; 232(4):219-22. PubMed ID: 2864402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
